Increasing Prevalence of Anthrax Infections Drive the Demand for Anthrax Treatment Market

Anthrax is a harmful disease that affects both animals and humans. It is a severe infection which is caused by Bacillus anthracis. Therefore, the growing prevalence and incidence of anthrax infections have developed a need for diagnostic approaches with improved sensitivity that can easily detect infection in low volume. Therefore, the rising demand of anthrax treatment due to increasing cases of anthrax infections is estimated to increase the growth of the global anthrax treatment market.

Access Full Report @ https://www.databridgemarketresearch.com/pt/reports/global-anthrax-treatment-market

Data Bridge Market Research analyses that the anthrax treatment market is expected to reach USD 674.63 Million by 2029 from USD 409.28 Million in 2021, growing at a CAGR of 6.6% in the forecast period of 2022 to 2029. The high adoption of sustainable and eco-friendly food service packaging is projected to propel the growth of the market because this food service packaging maintains the freshness of the product and prevents the food from biological contamination or exposure to chemical

Growing research funding and the development of novel therapies are expected to drive the market's growth rate

Research and development are required to modify the procedure used to treat different kinds of patients. The demand for anthrax treatment is growing globally. This is because companies are constantly focusing on research and development activities to provide effective treatment to patients successfully. In the last few years, several diagnostic methods have come forward for diagnosis with advanced technologies and various are being made to identify even the minimum volume of the parasite in the human body.

 Report Scope and Market Segmentation

Segment Analysis:

The anthrax treatment market is segmented on the basis of type, route of administration and end user.

• On the basis of type, the global anthrax treatment market is segmented into cutaneous anthrax, pulmonary anthrax and intestinal anthrax.

In 2022, the cutaneous anthrax segment of type segment is anticipated to dominate the anthrax treatment market

The cutaneous anthrax segment is expected to dominate the global anthrax treatment market with 93.02% market share because the cutaneous anthrax is found to be the highly prevalent anthrax which is accounting for more than 80% of the cases. According to the European Centre for Disease Prevention and Control, 9 cases of cutaneous anthrax from Hungary were reported in 2014.

• On the basis of route of administration, the global anthrax treatment market is segmented into oral, parenteral and others. In 2022, the parenteral segment is expected to dominate the global anthrax treatment market with 72.85% market share
• On the basis of end user, the global anthrax treatment market is segmented into government organization, hospitals, academic and research institutes, and others.

In 2022, the government organization segment is projected to hold the largest share of end user segment in the anthrax treatment market

The government organization segment is expected to dominate the global anthrax treatment market with 56.13% market share due to government initiatives for adaptation of infection control strategies, implementation of control measures and infection prevention such as administrative and engineering controls, personal protective equipment (PPE) and safe work practices.

Major Players

Data Bridge Market Research recognizes the following companies as the major anthrax treatment market players in anthrax treatment market Alembic Pharmaceuticals (India), Integrated Bio Therapeutics Inc. (U.S.), Zydus Group (India), Bayer AG (Germany), EMERGENT (U.S.), Sanofi (France), Elusys Therapeutics (U.S.), Porton Biopharma (China), Soligenix (U.S.), Takeda Pharmaceutical Company Limited (Japan), ARISTO Pharmaceuticals Private Limited (India), INDOCO REMEDIES LTD. (India).

Market Development

• In January 2022, Elusys Therapeutics, Inc. announced that they have finalized an agreement with Assistant Secretary for Preparedness and Response (ASPR) for the constant supply of ANTHIM (obiltoxaximab) which is an anthrax antitoxin in the U.S. Department of Health and Human Services (HHS) for use against a potential anthrax attack.
• In April 2022, Heat Biologics, Inc announced they had completed the acquisition with Elusys Therapeutics, Inc., a developer of ANTHIM® (obiltoxaximab) and commercial-stage Biodefense Company. This new product is used for the treatment for inhalation anthrax
• In June 2022, Emergent BioSolutions Inc. announced that the U.S. Food and Drug Administration (FDA) has given approval for reviewing the Biologics License Application (BLA) for AV7909. This is a new anthrax vaccine candidate who is evaluated for post-exposure prophylaxis of disease following confirmed or suspected exposure to Bacillus anthracis in people between the age group of 18 to 65 years of age with recommended antibacterial drugs
• In January 2022, Alembic Pharmaceuticals Limited declared that they have received final approval for its Abbreviated New Drug Application (ANDA) for Doxycycline Hyclate Delayed-Release Tablets USP, 200 mg, 150 mg, 100 mg and 75 mg from the U.S. Food & Drug Administration (USFDA). This is used only to prevent or treat infections that are strongly or proven suspected to be caused by susceptible bacteria. This results in growth of product portfolio of the company.

Regional Analysis

Geographically, the countries covered in the anthrax treatment market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South AmericaAs per Data Bridge Market Research analysis:

North America is the dominant region in anthrax treatment market during the forecast period 2022 - 2029

North America dominates the anthrax treatment market due to high government funding, presence of major players and supportive strategies in this region. There are also some factors such as initiatives by organizations for instance, the CDC supporting the growth of novel therapies for the treatment of anthrax. These are some major factors which is expected to further enhance the market's growth rate in this region. 

Asia-Pacific is estimated to be the fastest growing region in anthrax treatment market the forecast period 2022 - 2029

Asia-Pacific is expected to grow during the forecast period of 2022-2029 due the presence of fastest-growing economies and increasing technological advancement. Furthermore, the increasing prevalence of infections and presence of major market players are other factors expected to propel the market's growth rate in this region.

For more detailed information about anthrax treatment market report, click here – https://www.databridgemarketresearch.com/pt/reports/global-anthrax-treatment-market